Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Otsuka compound meets depression endpoint

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said OPC-34712 as an adjunct to antidepressant therapy met the

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE